💉

Semaglutide

Semaglutide is a once-weekly injectable drug that drives substantial, sustained weight loss and was the first medication in its class to also lower the risk of heart attacks and strokes in people with obesity. It's sold as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as a daily oral form. All three are the same molecule, dosed differently.
It works by mimicking GLP-1, a gut hormone released after eating, which tells the brain you're full, slows digestion, and improves how your body handles glucose. Most people are here because they want significant fat loss, want to fix blood sugar or cardiovascular risk, or both, and diet and exercise alone haven't gotten them there. The newer drug
💉
Tirzepatide
produces more weight loss than semaglutide by hitting a second receptor, but semaglutide has the deepest evidence base, the longest real-world track record at obesity doses, and dedicated cardiovascular and kidney outcomes data that tirzepatide doesn't yet have.
Deep-dive
How it works. Semaglutide is a long-acting analogue of GLP-1 (glucagon-like peptide-1), a hormone your gut releases after a meal. GLP-1 does three main things: it signals fullness to the brain, slows the rate food leaves your stomach, and prompts the pancreas to release insulin when glucose is high. Native GLP-1 has a half-life of about 2 minutes. Semaglutide has been modified (an attached fatty acid chain lets it bind albumin in the blood) so its half-life is about 7 days, which is why it's dosed once weekly.
The appetite effect is the part you feel. Meals sit longer in the stomach, so you stop being hungry between them. The constant background thinking about food, what people call "food noise," goes quiet. A 2023 narrative review frames this as a reduction in food cue reactivity, the brain's automatic response to food signals in the environment. Brain imaging work shows GLP-1 receptor activation dampens reward-related responses to high-calorie food cues in the mesolimbic dopamine system.
The weight-loss data. STEP-1 was the primary obesity trial, 1,961 adults with obesity or overweight with comorbidities, randomised to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight loss was 14.9% on semaglutide versus 2.4% on placebo. About 86% of treated participants lost at least 5% of body weight and 32% lost at least 20%. This was roughly double the loss of any obesity drug previously approved.
Longer-term, the SELECT trial's prespecified body weight analysis followed 17,604 adults for up to 4 years and found weight loss continued through week 65 and was sustained out to 208 weeks, with a mean reduction of 10.2% versus 1.5% on placebo. This is the longest weight-loss follow-up for any GLP-1 drug to date.
Versus tirzepatide. SURMOUNT-5, the first head-to-head trial, randomised 751 adults with obesity to maximum tolerated tirzepatide or semaglutide for 72 weeks. Tirzepatide produced 20.2% mean weight loss versus 13.7% on semaglutide. Semaglutide had higher rates of nausea and slightly more GI-related discontinuations. The two drugs feel different: semaglutide skews toward nausea and constipation, tirzepatide more toward diarrhoea. Tirzepatide currently wins on weight loss magnitude. Semaglutide currently wins on depth of outcomes evidence.
Cardiovascular outcomes. This is where semaglutide stands apart. SELECT randomised 17,604 adults with obesity and established cardiovascular disease but no diabetes to semaglutide 2.4 mg or placebo, followed for a median of 39.8 months. Major adverse cardiovascular events (death from CV causes, non-fatal heart attack, or non-fatal stroke) dropped by 20%. This was the first obesity drug ever to show a hard cardiovascular outcome benefit, and it led to FDA approval for cardiovascular risk reduction in 2024. Tirzepatide doesn't yet have a comparable trial result.
Diabetes. Across the SUSTAIN trial program for type 2 diabetes, semaglutide 1.0 mg weekly reduced HbA1c by roughly 1.5-1.8 percentage points and produced weight loss of 4-6 kg, more than any other GLP-1 drug at the time of its diabetes approval. It's been a first-line non-insulin option for years.
Kidney protection. The FLOW trial randomised 3,533 adults with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg or placebo. The composite of major kidney events, cardiovascular events, and all-cause death dropped by 24%. This led to FDA approval for chronic kidney disease in type 2 diabetes in January 2025 and is the strongest kidney outcome data for any GLP-1 drug.
Heart failure. STEP-HFpEF tested semaglutide 2.4 mg in 529 adults with obesity-related heart failure with preserved ejection fraction. After 52 weeks, the heart failure symptom score (KCCQ-CSS) improved by 16.6 points versus 8.7 with placebo, and 6-minute walk distance improved by 21 metres. Symptom benefits were largely independent of weight loss, suggesting direct effects on the failing heart. STEP-HFpEF-DM replicated this in patients with type 2 diabetes.
Liver. Roughly a third of adults have metabolic dysfunction-associated steatotic liver disease (MASLD). A phase 2 trial in MASH found semaglutide 0.4 mg daily resolved MASH without worsening fibrosis in 59% of treated participants versus 17% on placebo. The newer ESSENCE phase 3 trial confirmed the effect. Liver fat clears reliably alongside the weight loss.
Alcohol and reward behaviours. Anecdotal reports of reduced drinking, smoking, and other compulsive behaviours have been consistent enough to push the field to test them. A 2025 phase 2 RCT in 48 adults with alcohol use disorder found 9 weeks of low-dose semaglutide reduced weekly alcohol craving and average drinks per drinking day versus placebo. A separate 83,825-patient retrospective cohort study found semaglutide associated with a 50-56% lower risk of new or recurrent alcohol use disorder compared to other weight-loss drugs. Mechanism is GLP-1 receptor activity in mesolimbic reward circuits, the same pathway that dampens food cravings. The clinical question is whether this is enough to matter at the level of an individual choosing to drink less. For most users, it's a noticeable side benefit, not a treatment.
Women. Women make up around 70% of GLP-1 users and respond differently. Pooled STEP analyses found women lost substantially more weight than men: −14.0% vs −8.0% treatment difference versus placebo in STEP-1, with similar patterns in STEP-2 and STEP-4. A 2024 endocrinology review summarises the mechanism: women have lower body weight (so higher effective drug exposure), oestrogen amplifies GLP-1 receptor signalling, and gastric emptying is slower in women at baseline. The trade-off is roughly 2x higher rates of nausea and vomiting in women, and higher rates of treatment discontinuation. In the STEP-HFpEF sex analysis, women lost 9.6% versus 7.2% in men, but symptom and functional improvements were the same in both, suggesting the heart benefit isn't just downstream of weight loss. Significant weight loss can also disrupt menstrual cycles temporarily and often improves PCOS-related cycle irregularity as insulin sensitivity rises.
Body composition. The STEP-1 DXA substudy found 15% body weight loss was made up of −19.3% fat mass and −9.7% lean body mass, so roughly two-thirds fat to one-third lean. The proportion of body that was lean tissue actually rose. The SEMALEAN study, a 12-month prospective DXA trial in 106 patients, found lean mass dropped 3 kg by month 7 then stabilised, while handgrip strength rose by 4.5 kg and the prevalence of sarcopenic obesity fell from 49% to 33%. The lean mass loss is real but the functional outcome appears to improve, presumably because what's lost is largely the supportive tissue that's no longer needed once the fat mass drops. Resistance training and adequate protein move the needle further.
What it doesn't do as well. Versus tirzepatide, weight loss is smaller. Versus retatrutide and CagriSema, smaller again. It doesn't fix the underlying physiology, so stopping the drug brings weight back. The STEP-1 extension found participants regained two-thirds of their lost weight in the year after stopping. Long-term use is the practical model unless the window of weight loss is used to lock in habits.
Limits of the evidence. Obesity-dose use has been widespread only since 2021. Long-term data on cancer signals (beyond thyroid C-cell tumours in rodents), pregnancy outcomes, very long-term bone density, and stop-restart effects on body composition are open questions. Lower-dose use in diabetes has been studied since 2017 with a reassuring safety record, but the specific question of decades at 2.4 mg isn't answered yet.

Dosage

  • Schedule (weight management and CV/kidney indications): Once-weekly subcutaneous injection into abdomen, thigh, or upper arm. Rotate sites. The standard Wegovy ladder is 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, stepping up every 4 weeks. Full titration to 2.4 mg takes about 16 weeks
  • Schedule (type 2 diabetes, Ozempic): Same pen, lower maintenance. 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg, stepping up every 4 weeks based on glycaemic response. Most people land at 1.0 or 2.0 mg
  • Starting dose: 0.25 mg weekly for 4 weeks. This is a tolerance dose, not a therapeutic dose. Don't expect significant weight loss in this window. Its job is to let the gut adapt to slowed gastric emptying
  • Titration: Step up every 4 weeks as tolerated. If side effects at a step are significant, hold that dose for another 4 weeks before going up. There's no rush, and slower titration genuinely reduces nausea
  • Maintenance: 2.4 mg for weight loss and cardiovascular risk reduction. 1.0 mg for kidney protection in type 2 diabetes (this is the FLOW trial dose). 1.0 or 2.0 mg for glucose control in type 2 diabetes
  • Women generally do well starting at 0.25 mg and may need slower titration. Roughly 2x higher rate of nausea and vomiting means a 6-week hold at each step is reasonable if GI symptoms don't settle. Lower body weight also means higher effective exposure, so many women find their effective dose at 1.0 or 1.7 mg rather than needing 2.4 mg
  • Older adults (60+) often respond at lower doses. 1.0 or 1.7 mg is frequently enough, and the muscle preservation calculus matters more at this age
  • Oral semaglutide (Rybelsus): 3 mg → 7 mg → 14 mg daily, stepped up every 30 days. Take on an empty stomach with at most 4 oz of water, 30 minutes before any food, drink, or other medication. Oral bioavailability is only 1-2% so the timing rules are not optional. Weight loss and glucose effects at 14 mg are comparable to roughly 0.5-1.0 mg of the injectable. Newer 25 mg and 50 mg oral doses are being trialled and approved in some jurisdictions for weight management
  • Missed doses: Take the weekly injection within 5 days (120 hours) of the scheduled day. Beyond that, skip and resume the normal schedule. Always at least 48 hours between consecutive doses
  • Forms: Branded Wegovy (weight) and Ozempic (diabetes) are pre-filled pens, same molecule different dose ranges. Rybelsus is the daily oral tablet. Compounded semaglutide is widely sold via telehealth in vials at variable concentration and requires drawing with an insulin syringe. Source matters more than price here, compounded quality varies significantly
  • Stack with resistance training and protein. This is not optional. 1.6-2.0 g protein per kg of target body weight per day, plus 2-3 resistance sessions weekly. Without this, a meaningful share of what you lose is lean mass. Consider
    Creatine
    Creatine
    at 3-5 g daily for the muscle preservation effect
  • Don't stack with other GLP-1 drugs (tirzepatide, liraglutide, dulaglutide). You'll dose-stack side effects without benefit

Here's what you can expect

Appetite suppression starts in the first 1-2 weeks even at the 0.25 mg starter dose. The signal is unmistakable. You stop thinking about food between meals. Portions you used to finish feel like too much. The constant background hunger goes quiet. Many users describe this as "food noise" turning off.
Weight on the scale moves slowly at first. The starter and 0.5 mg doses aren't enough to drive significant loss for most people, that's expected. Loss accelerates as you titrate up. By 1.0-1.7 mg most people are losing 0.5-1% of body weight per week. By 2.4 mg maintenance the rate flattens but continues for months, the SELECT data shows loss still accumulating at 65 weeks.
Meals taste different. Greasy food and alcohol feel heavier and less appealing. Many users report alcohol hits harder on much less, because slowed gastric emptying changes how fast it reaches the bloodstream and because the reward signal seems blunted. Cravings for sweet and processed food fade. Some people lose interest in foods they used to love, which can read as a loss of pleasure.
Energy can dip in the first 4-8 weeks while the body adjusts to a calorie deficit you didn't choose consciously. This usually settles. If it doesn't, you're probably under-eating protein or undersleeping.
Women often notice cycle changes in the first few months: lighter or skipped periods, shifted timing. This usually settles within 3-6 months as weight stabilises. Women with PCOS often see cycles regularise as insulin sensitivity improves.
Clothes start fitting differently before the scale shifts dramatically, especially around the waist. Waist circumference and visceral fat drop disproportionately, which is the metabolically important kind to lose.
Facial fat thins. "Ozempic face" got named for a reason. The face has discrete fat pads that lose volume alongside the rest of the body, and the skin doesn't always retract at the same pace. Most apparent in people losing 15%+ of body weight, and more visible over 40.
If you stop, expect regain. Roughly two-thirds of lost weight returns within a year if you do nothing else. The drug is doing the work. When it leaves, the appetite signals return. Either plan for long-term use, or use the window to lock in the habits that hold the new weight afterward.

Side effects & risks

  • Gastrointestinal (very common, 40-50%). Nausea, constipation, diarrhoea, vomiting, bloating. Worst in the first 2-3 weeks after each dose increase, then settles. Manage by eating smaller portions, prioritising protein, hydrating aggressively, and reducing fatty and greasy meals. For constipation,
    Magnesium
    Magnesium
    glycinate before bed and adequate fibre work better than laxatives. Nausea is worst 24-48 hours after injection. Inject in the evening if you'd rather sleep through the worst of it. Women experience nausea and vomiting at roughly 2x the rate men do
  • Muscle loss. Around 30% of weight lost is lean mass without active intervention. Resistance training 2-3x weekly plus 1.6-2.0 g/kg protein daily roughly halves this. Track grip strength or a single lift like a goblet squat or deadlift as a proxy. If strength drops, eat more protein, lift more
  • Hair loss. Telogen effluvium from rapid weight loss, not a direct drug effect. Diffuse shedding starting 2-4 months in, usually peaks at 6 months and regrows by 9-12 months. Adequate protein, iron, and zinc help
  • Gallbladder disease (1-3%). Rapid weight loss mobilises stored fat into the liver, oversaturating bile with cholesterol and raising gallstone risk. Symptoms: right upper abdominal pain after fatty meals, fever, jaundice. Persistent right upper quadrant pain warrants imaging
  • Pancreatitis (rare, <0.2% in trials). Severe central abdominal pain radiating to the back, often with nausea and vomiting. Stop the drug and seek medical attention immediately. People with a history of pancreatitis should approach this drug cautiously
  • Heart rate elevation (modest). Resting heart rate typically rises 2-4 bpm. You may notice slightly reduced HRV on a wearable. Mechanical, not a recovery problem
  • Thyroid C-cell tumours. Found in rodents but not confirmed in humans across 10+ years of GLP-1 drug use. FDA boxed warning. Contraindicated if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
  • NAION (rare). Non-arteritic anterior ischaemic optic neuropathy is sudden, painless vision loss in one eye. A 2024 Harvard case-control study found semaglutide users had roughly 4x the NAION risk of non-GLP-1 users in a specialty clinic cohort. A subsequent multi-centre analysis and a Danish-Norwegian registry study found weaker or no signal. A US veterans cohort found a roughly 2x risk versus SGLT2 inhibitors. Absolute incidence is low (~0.3% over 2 years), but sudden vision changes warrant immediate evaluation
  • Gastroparesis. Slowed gastric emptying is the desired mechanism, but in a small minority it persists past dose adjustments and becomes symptomatic (chronic nausea, early satiety, delayed digestion). Active litigation exists. Reversible in most cases after stopping
  • Mood flattening (anecdotal but consistent). Many users report a general dampening of motivation, pleasure, and interest in things they used to enjoy, food first but sometimes broader. Not depression in the clinical sense, more an overall flattening. Likely downstream of reduced palatable food intake and dopamine reward signalling. Usually resolves on discontinuation
  • Pregnancy. Stop semaglutide at least 2 months before trying to conceive. Half-life is long (7 days) and reproductive safety data is limited. Fertility often improves significantly with weight loss, which means accidental pregnancy in the first few months is more common than people expect, especially in women with PCOS who weren't getting regular ovulation
  • Alcohol. Tolerance drops noticeably. The same drink hits harder on less, and the reward signal seems blunted. Plan accordingly
  • Long-term safety. Diabetes-dose data goes back to 2017 and is reassuring. Obesity-dose data extends to about 4 years from SELECT. Decades-long exposure at 2.4 mg isn't yet characterised

🩸

Blood markers

HbA1c, fasting glucose, fasting insulin at baseline. HOMA-IR (calculated from fasting glucose and insulin) tells you where your insulin resistance sits. Recheck at 3 and 6 months. If A1c is in the prediabetic range (5.7-6.4%), expect a meaningful drop.
Lipid panel (LDL, HDL, triglycerides, ApoB if available) at baseline. Triglycerides come down substantially with weight loss. LDL and ApoB improve modestly. HDL doesn't move much, that responds to cardio and diet. Recheck at 3 and 6 months, then annually.
ALT and AST at baseline. ALT rises with liver fat. If you're carrying significant abdominal weight, ALT is often quietly elevated and tracks down as the liver clears. Recheck at 3 and 6 months.
Amylase and lipase at baseline given pancreatitis risk. Don't recheck routinely. Recheck only if you develop persistent upper abdominal pain.
Creatinine and eGFR, urine albumin-to-creatinine ratio (UACR) at baseline. Kidney function should be stable or improve. UACR is particularly worth tracking if you have type 2 diabetes or hypertension, FLOW showed the kidney benefit tracks with reductions in albuminuria. Recheck at 6 months and annually.
TSH at baseline. Useful as a thyroid reference point given the boxed warning. Persistent neck lump, voice change, or trouble swallowing warrants direct imaging.
CBC including ferritin and B12 at baseline if you're a woman, vegetarian, or over 50. Rapid weight loss plus reduced appetite can drop iron and
Vitamin B12
Vitamin B12
stores, which compounds fatigue and hair loss. Recheck at 6 months.
DXA scan at baseline if you can access it. Lean mass loss is the main body-composition risk. Tracking with a scale alone hides whether you're losing fat or muscle. Recheck at 6 and 12 months. If lean mass is dropping faster than expected, increase protein and resistance training before adjusting the drug.
Blood pressure at baseline and monthly through titration. Usually drops with weight loss. If you're on antihypertensives, doses may need to come down to avoid lightheadedness.
Resting heart rate at baseline. Expect a 2-4 bpm rise. Anything more is worth a conversation with whoever prescribed it.
Prescription only in the US, UK, EU, Australia, and most other jurisdictions. Compounded versions are available via telehealth in some countries when supply is constrained.